Hospital
Franciscan Health Lafayette
Franciscan Health Lafayette was paid $38.56M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoFRANCISCAN HEALTH LAFAYETTE
LAFAYETTE, IN 47905
LAFAYETTE, IN 47905
33aNPI1356435341assigned 10/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.56M
24GClaims643,244
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#8 of 69
Median peer was paid$9.76M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,511 | $2.25M | |
| 2019 | 92,258 | $4.52M | |
| 2020 | 65,281 | $4.25M | |
| 2021 | 85,325 | $6.38M | |
| 2022 | 114,828 | $8.49M | |
| 2023 | 102,895 | $7.90M | |
| 2024incomplete | 66,146 | $4.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 51,081 | 42,605 | $7.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 53,459 | 47,309 | $7.75M |
| 71045 | Radiologic examination, chest; single view | 7.4% | 22,073 | 18,707 | $2.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.0% | 16,706 | 13,755 | $2.30M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.8% | 3,931 | 1,455 | $1.85M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.3% | 24,289 | 19,786 | $1.64M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 9,723 | 8,756 | $1.47M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.0% | 16,427 | 14,586 | $1.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 2,863 | 2,393 | $1.00M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.2% | 8,359 | 3,072 | $852K |
| J7030 | Infusion, normal saline solution , 1000 cc | 2.0% | 19,875 | 15,728 | $786K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 9,259 | 3,452 | $778K |
124 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.0% | 9,839 | $768K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 19,560 | $680K |
| 99218 | 1.5% | 1,214 | $592K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 13,033 | $548K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 5,881 | $542K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 15,859 | $531K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 495 | $513K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,221 | $380K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 53,316 | $284K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,607 | $275K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,945 | $251K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,998 | $228K |
| 80053 | Comprehensive metabolic panel | <1% | 28,080 | $219K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,710 | $185K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,448 | $160K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,950 | $133K |
| 99221 | <1% | 220 | $125K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 727 | $125K |
| 84484 | <1% | 13,900 | $111K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,895 | $102K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,018 | $99K |
| 81025 | <1% | 16,429 | $95K | |
| 87634 | <1% | 1,572 | $87K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,730 | $82K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,492 | $77K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 49 | $75K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 700 | $72K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,016 | $65K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,205 | $62K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,416 | $60K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 684 | $59K |
| 81001 | <1% | 24,898 | $55K | |
| 83690 | <1% | 13,530 | $49K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,715 | $47K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,504 | $42K |
| 87430 | <1% | 4,730 | $41K | |
| 80076 | <1% | 9,090 | $40K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 488 | $32K |
| Q3014 | Telehealth originating site facility fee | <1% | 741 | $31K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,308 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 141 | $26K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,554 | $23K |
| 83735 | <1% | 5,374 | $21K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 773 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,903 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 119 | $19K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 131 | $19K |
| 80061 | Lipid panel | <1% | 1,966 | $18K |
| 97162 | <1% | 221 | $16K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 727 | $16K |
| 85610 | <1% | 7,111 | $14K | |
| 83880 | <1% | 706 | $14K | |
| 11043 | <1% | 23 | $14K | |
| 87081 | <1% | 3,340 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 568 | $11K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 568 | $11K |
| 83605 | <1% | 2,170 | $11K | |
| 87631 | <1% | 96 | $11K | |
| 80050 | General health panel | <1% | 81 | $10K |
| 81003 | <1% | 5,729 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $8K |
| 87807 | <1% | 1,058 | $7K | |
| 97163 | <1% | 95 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 344 | $7K |
| 80179 | <1% | 443 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 999 | $7K |
| 80143 | <1% | 407 | $6K | |
| 82077 | <1% | 462 | $6K | |
| 94010 | <1% | 78 | $6K | |
| 90839 | <1% | 166 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 432 | $4K |
| 97167 | <1% | 46 | $3K | |
| 94761 | <1% | 1,286 | $3K | |
| 84100 | <1% | 399 | $2K | |
| 82607 | <1% | 251 | $2K | |
| 71250 | <1% | 13 | $2K | |
| 92523 | <1% | 13 | $2K | |
| 85379 | <1% | 288 | $2K | |
| 85730 | <1% | 738 | $2K | |
| 84702 | <1% | 205 | $1K | |
| 87077 | <1% | 385 | $1K | |
| 84145 | <1% | 68 | $1K | |
| 83970 | <1% | 47 | $990.46 | |
| 73630 | <1% | 52 | $870.42 | |
| 82570 | <1% | 274 | $787.95 | |
| 82652 | <1% | 38 | $759.39 | |
| 84439 | <1% | 135 | $732.75 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,670 | $617.73 |
| 84550 | <1% | 250 | $610.81 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 15 | $575.64 |
| 84156 | <1% | 273 | $574.91 | |
| 82150 | <1% | 144 | $539.91 | |
| 87210 | <1% | 194 | $377.24 | |
| 97116 | <1% | 18 | $365.51 | |
| 87186 | <1% | 69 | $361.20 | |
| 73110 | <1% | 17 | $343.44 | |
| 88342 | <1% | 42 | $321.90 | |
| 96376 | <1% | 92 | $317.40 | |
| 83525 | <1% | 25 | $177.84 | |
| 84481 | <1% | 14 | $165.83 | |
| 84681 | <1% | 14 | $162.21 | |
| 86803 | <1% | 13 | $143.26 | |
| 82550 | <1% | 30 | $99.80 | |
| 87070 | <1% | 28 | $97.25 | |
| 82043 | <1% | 14 | $43.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,419 | $40.52 |
| 85045 | <1% | 16 | $40.24 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,755 | $31.67 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 469 | $0.54 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 174 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 1,740 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 651 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 76 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 333 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 42 | $0.00 |
| A9270 | Non-covered item or service | 0% | 57 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 74 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 603 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 427 | $0.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 72 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 54 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILSON, TERRANCE (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Franciscan Health Crawfordsville | Crawfordsville, IN | $13.47M |
| Franciscan Health Lafayette | Lafayette, IN | $8.81M |
| Franciscan Health Rensselaer, INC. | Rensselaer, IN | $4.16M |
| Franciscan Health Rensselaer, INC. | Brook, IN | $177K |
| Franciscan Health Rensselaer, INC. | Wheatfield, IN | $97K |
| Franciscan Health Lafayette | Lafayette, IN | $28K |
| Franciscan Health Lafayette | Lafayette, IN | $903.92 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.